Latest News and Press Releases

RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes...

Autolus will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT.

CARGO Therapeutics Provides Corporate Update

○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD...

Dublin, March 13, 2025 (GLOBE NEWSWIRE) -- The "Allogeneic CAR-T Cell Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global allogenic...

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

PARIS, March 06, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. The Chimeric...

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

Dublin, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035" report has been added to ResearchAndMarkets.com's offering. The global CAR...